Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia Academic Article uri icon

Overview

MeSH Major

  • Benzoates
  • Genetic Diseases, X-Linked
  • Hydrazines
  • Pyrazoles
  • Thrombocytopenia
  • Wiskott-Aldrich Syndrome

abstract

  • (1) the reduced platelet activation observed in WAS/XLT is primarily due to the microthrombocytopenia; and (2) although the eltrombopag-induced increase in platelet production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet count but not platelet activation in the majority of WAS/XLT patients. This trial was registered at www.clinicaltrials.gov as #NCT00909363.

publication date

  • September 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4729539

Digital Object Identifier (DOI)

  • 10.1182/blood-2014-09-602573

PubMed ID

  • 26224646

Additional Document Info

start page

  • 1367

end page

  • 78

volume

  • 126

number

  • 11